Intracellular Enterprise Value over EBITDA from 2010 to 2024
ITCI Stock | USD 74.54 2.17 3.00% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (42.41) | Current Value (40.29) | Quarterly Volatility 11.35186913 |
Check Intracellular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intracellular main balance sheet or income statement drivers, such as Interest Expense of 8.9 M, Total Revenue of 485.3 M or Gross Profit of 449.9 M, as well as many exotic indicators such as Price To Sales Ratio of 14.12, Dividend Yield of 0.0 or PTB Ratio of 7.67. Intracellular financial statements analysis is a perfect complement when working with Intracellular Valuation or Volatility modules.
Intracellular | Enterprise Value over EBITDA |
About Intracellular Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Intracellular income statement, its balance sheet, and the statement of cash flows. Intracellular investors use historical funamental indicators, such as Intracellular's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although Intracellular investors may use each financial statement separately, they are all related. The changes in Intracellular's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Intracellular's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Intracellular Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Intracellular. Please read more on our technical analysis and fundamental analysis pages.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Intracellular Correlation against competitors. Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 4.843 | Quarterly Revenue Growth 0.503 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.